Provided herein are method of analyzing genomic and metabolomic data from fungi to identify relationships between biosynthetic gene clusters and mass spectrometric features of metabolites.

The disclosure provides methods and compositions for affecting the development of antigen presenting cell (APC, e.g., a macrophage or dendritic cell). The methods include maturing an APC, promoting anti-inflammatory phenotype, promoting development of a T regulatory cell (Treg) from a naive T cell. The methods generally include exposing an APC to a tryptophan derived microbiota metabolite (TDMM), such as an anti-inflammatory or pro-mucosal TDMM, and permitting the APC to mature. In some embodiments, the conditioned APC is exposed to a naive T cell to further promote development of a T regulatory cell (Treg). In some embodiments, the TDMM is selected from the group consisting of indole, indole-3-acetate, 5-hydroxyindole, and indole-3-pyruvate.

A method for preoperatively characterizing an individual patient's biomechanic function in preparation of implanting a prosthesis is provided. The method includes subjecting a patient to various activities, recording relative positions of anatomy during said various activities, measuring force environments responsive to said patient's anatomy and affected area during said various activities, characterizing the patient's biomechanic function from said relative positions and corresponding force environments, inputting the measured force environments, relative positions of knee anatomy, and patient's biomechanic function characterization into one or more computer simulation models, inputting a computer model of the prosthesis into said one or more computer simulation models, and manipulating the placement of the prosthesis in the computer simulation using said patient's biomechanic function characterization and said computer model of the prosthesis to approximate a preferred biomechanical fit of the prosthesis.

A method for preoperatively characterizing an individual patient's biomechanic function in preparation of implanting a prosthesis is provided. The method includes subjecting a patient to various activities, recording relative positions of anatomy during said various activities, measuring force environments responsive to said patient's anatomy and affected area during said various activities, characterizing the patient's biomechanic function from said relative positions and corresponding force environments, inputting the measured force environments, relative positions of knee anatomy, and patient's biomechanic function characterization into one or more computer simulation models, inputting a computer model of the prosthesis into said one or more computer simulation models, and manipulating the placement of the prosthesis in the computer simulation using said patient's biomechanic function characterization and said computer model of the prosthesis to approximate a preferred biomechanical fit of the prosthesis.

The invention describes the method allowing for efficient predictive ranking of clinical efficiencies of the existing targeted medicinal products for individual patient with proliferative or oncology disease. The method makes it possible to use a wide range of experimental data received from the patients' pathological tissue samples and relevant control samples: information on gene mutations, transcription factor binding profile, protein (considering harmonization), mRNA (considering harmonization) and microRNA expression strength. The method also uses information on molecular targets of the medicinal products. This method can be automated to prevent potential errors associated with manual calculation and makes it possible to consider patient-specific changes in hundreds and thousands molecular pathways which include tens and hundreds of gene products. This method also considers the features and mode of action of various classes of target drugs. Using this method will enable selecting a medicinal product for the patient based on the analysis of objective individual changes occurred in the pathological tissue.

A method and system for in-silico testing of actives on human skin is described. The present invention discloses a micro and macroscopic level model of the skins upper protective layer Stratum-Corneum. The invention presents a multi-scale modeling framework for the calculation of diffusion and release profile of different actives like drugs, particles and cosmetics through developed skin model using molecular dynamics simulations and computational fluid dynamics approach. The systems consist of a molecular model of the skin's upper layer stratum corneum and permeate molecules. The system also consists of a macroscopic transport model of stratum corneum. The transport model is used to generate the release profile of the active molecule.

A method and system for in-silico testing of actives on human skin is described. The present invention discloses a micro and macroscopic level model of the skins upper protective layer Stratum-Corneum. The invention presents a multi-scale modeling framework for the calculation of diffusion and release profile of different actives like drugs, particles and cosmetics through developed skin model using molecular dynamics simulations and computational fluid dynamics approach. The systems consist of a molecular model of the skin's upper layer stratum corneum and permeate molecules. The system also consists of a macroscopic transport model of stratum corneum. The transport model is used to generate the release profile of the active molecule.

The invention relates to the human gut microbiota and its metabolic capabilities. In particular to a method evidencing the functional heterogeneity in the fermentation capabilities of the healthy human gut microbiota. More particularly, the invention provides an in silico method for predicting a response to different dietary fibres based on the analysis and measuring of the fermentation or metabolic capabilities of a subjects gut microbiota as well as a computer software product and an apparatus for predicting a response of a subject to different dietary fibres.

The invention relates to the human gut microbiota and its metabolic capabilities. In particular to a method evidencing the functional heterogeneity in the fermentation capabilities of the healthy human gut microbiota. More particularly, the invention provides an in silico method for predicting a response to different dietary fibres based on the analysis and measuring of the fermentation or metabolic capabilities of a subjects gut microbiota as well as a computer software product and an apparatus for predicting a response of a subject to different dietary fibres.

This disclosure provides methods, systems, compositions, and kits for the multiplexed detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, systems, compositions, and kits wherein multiple analytes may be detected in a single sample volume by acquiring a cumulative measurement or measurements of at least one quantifiable component of a signal. In some cases, additional components of a signal, or additional signals (or components thereof) are also quantified. Each signal or component of a signal may be used to construct a coding scheme which can then be used to determine the presence or absence of any analyte.